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Abstract
Stroke is a leading cause of neurological injury characterized by impairments in multiple neurological domains including cognition, language, sensory and motor functions. Clinical recovery in these domains is tracked using a wide
range of measures that may be continuous, ordinal, interval or categorical in nature, which can present challenges
for multivariate regression approaches. This has hindered stroke researchers’ ability to achieve an integrated picture
of the complex time-evolving interactions among symptoms. Here, we use tools from network science and machine
learning that are particularly well-suited to extracting underlying patterns in such data, and may assist in prediction
of recovery patterns. To demonstrate the utility of this approach, we analyzed data from the NINDS tPA trial using the
Trajectory Profile Clustering (TPC) method to identify distinct stroke recovery patterns for 11 different neurological
domains at 5 discrete time points. Our analysis identified 3 distinct stroke trajectory profiles that align with clinically relevant stroke syndromes, characterized both by distinct clusters of symptoms, as well as differing degrees of
symptom severity. We then validated our approach using graph neural networks to determine how well our model
performed predictively for stratifying patients into these trajectory profiles at early vs. later time points post-stroke.
We demonstrate that trajectory profile clustering is an effective method for identifying clinically relevant recovery
subtypes in multidimensional longitudinal datasets, and for early prediction of symptom progression subtypes in
individual patients. This paper is the first work introducing network trajectory approaches for stroke recovery phenotyping, and is aimed at enhancing the translation of such novel computational approaches for practical clinical
application.
Keywords: Stroke recovery, Disease subtyping, Network science, Network medicine, Graph neural networks
1 Introduction
1.1 Dynamic and multi‑domain nature of stroke recovery

The process of neurological recovery after brain injuries
such as stroke entails complex interactions among multiple variables that change dynamically over time [1, 2].
It is well known that the degree of recovery after stroke
varies widely between individuals [3–6], where each
patient’s recovery pattern uniquely reflects the combined
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influence of their lesion size and location [7], baseline
health status, time to initial treatment [8], and response
to medical treatment or rehabilitation, among many
other intrinsic and extrinsic factors. Recovery trajectories
furthermore vary depending on the specific neurological
domain(s) affected (i.e., for motor, language, or sensory
impairments) [9, 10], and each of these symptoms may
show varying responsiveness to treatment. For example,
language problems (aphasia), right-sided motor symptoms, and spatial perceptual problems (hemineglect) are
reportedly less responsive than other symptoms to treatment with tissue plasminogen activator (tPA) [11]. Stroke
recovery is therefore notoriously heterogeneous in terms
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of the type and severity of residual symptoms, as well as
the timecourse of progression and/or resolution of those
symptoms [12].
An important goal for stroke research is to reduce
the ‘noise’ arising from this inherent heterogeneity by
stratifying patients who are likely to have similar symptom trajectories. The heterogeneity of symptoms and
time-varying recovery patterns inherent to stroke make
it an area especially well-suited area for data-driven
approaches. The increasing availability of large scale
stroke datasets has led to a recent explosion in the use
of data-science methods for stroke research [13]. For
example, machine learning analyses of stroke clinical data
[12, 14] have been used to characterize symptom clusters
[15], predict outcomes [3], and define composite measures of recovery [16].
1.2 Limitations of conventional regression and machine
learning approaches versus network science

While machine learning (ML) approaches have been successful in a variety of analytical tasks, they often present
challenges for interpretation and subsequent application. By contrast, network science tools are explicit in
their modeling, making them more useful for studying
medical data where clinical interpretation is paramount.
Additionally, typical ML approaches focus on prediction,
while taking the outcome itself at face value; in contrast,
network approaches attempt to improve how the outcome itself is captured. While ML tools may not be as
readily interpretable as network approaches for various
types of analyses (such as understanding the interactions
that underlie disease recovery patterns) ML still presents
several desirable properties, particularly in terms of datadriven predictive ability, and may therefore be useful for
prognostication of patient recovery patterns.
Conventionally, statistical tools such as mixed-effects
regression are used for modeling longitudinal data in disciplines where repeated measures designs are particularly
relevant, such as education, motor learning, and psychology [17–19]. Mixed-effects models have tremendous
flexibility in their ability to accommodate different types
of study designs and data types [20–22]. Such models are
thus increasingly used in fields like neurorehabilitation
where serial measures of recovery constitute a central
focus [2, 18, 23]. Most importantly for our present purposes, mixed-effect models provide a means of estimating a unique trajectory for each person by combining the
models fixed-effects with random-slopes and intercepts
to obtain a unique (non)linear trajectory for each person.
These trajectories can then be compared across different
domains of recovery to see which domains covary or vary
independently from each other.
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1.3 Network science and trajectory profile clustering
for stroke research

Insights into the complex patterns of symptom evolution can be gained through the computational power
of network analysis. The field of network medicine
[24] studies disease manifestation and progression as
a function of multiple interacting disease variables,
which may be of similar or different types. Network
approaches also produce intuitive data visualizations
that can facilitate interaction between clinicians and
data scientists to yield novel insights on disease. However, with few exceptions, most network medicine studies have focused on biomolecular data [25, 26] rather
than characterizing patients’ patterns of symptom progression over time.
Recently, Krishnagopal et al. [27] introduced a network-based approach called Trajectory Profile Clustering (TPC) that groups patients based on similar
patterns of symptom evolution. The intuitiveness and
ability of TPC to integrate variables on multiple different scales make it especially useful for studying disease
severity, progression, and recovery. Multi-layer [28]
types of trajectory clustering have also shown success
in clinically validated disease trajectory prediction in
Parkinson’s disease. We argue that TPC offers unique
advantages for stroke recovery research based on its
ability to simultaneously: (i) identify the dominant variables that differentiate stroke recovery subtypes; (ii)
account for temporal disease progression patterns; and
(iii) delineate distinct symptom groupings. This
paper is the first work introducing network trajectory
approaches for stroke recovery phenotyping, and is
aimed at enhancing the translation of such novel computational approaches for practical clinical application.
When analyzing recovery trajectories with TPC, an
obvious question that arises is at what stage do patients
begin to stratify into distinct trajectory clusters (i.e.,
when do they begin to show symptom patterns unique
to their recovery subtype)? The timing of medical treatments might be one important influence on the timecourse of recovery subtype stratification. For example
in stroke, stratification might be expected to occur
based on when patients receive treatments such as
tPA or clot retrieval. Naively, this may appear to be a
problem of simply measuring the differences between
trajectory subtypes at each timepoint. However, since
treatment efficacy for the same individual at different
timepoints is not unrelated, more sophisticated tools
are required to extract the timescale of separation. We
can investigate these questions through graphical tools
such as graph neural networks in machine learning.
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1.4 Graph neural networks for the study of neurological
disorders

The field of machine learning has been revolutionized by
recent advances in deep neural networks, especially convolutional neural networks (CNNs) [29]. Conventionally,
CNNs use local connections, shared weights and multiple layers to extract representations of data. However,
CNNs work in a Euclidean domain and are best suited for
use with images. By contrast, other deep learning methods can operate on a graph domain (i.e., graph neural
networks or GNNs) [30]. Convolutional variants of graph
neural networks provide a framework for transferring
deep learning operators into a non-Euclidean (graphical) domain, and have been successful in a variety of tasks
such as graph classification, node identification, link prediction in protein interactions, knowledge graphs, and
social network analysis, among others. Of particular
interest here, they have been successfully applied to study
neurological disorders including Alzheimer’s disease and
autism [31, 32], and could similarly have utility in the
study of stroke.

2 Stroke dataset analyzed
To demonstrate the utility of using TPC and GNN for
stroke recovery research, we analyzed cases from the
well-characterized NINDS tPA trial data set [33]. This
study was a randomized, double-blinded, placebo-controlled trial that compared the effects of intravenous tPA
(a thrombolytic agent used in ischemic stroke to dissolve
blood clots) versus placebo treatment in 624 patients.
The data set captured neurologic deficits on the NIH
Stroke Scale (NIHSS) [34], which is the most widely used
measurement scale for stroke neurologic deficits, and has
well-defined clinimetric properties [35, 36]. Each item is
scored on a scale (from 0–2 or 0–5), with higher values
indicating greater stroke severity. The NINDS tPA trial
captured NIHSS scores across 5 time points: at hospital
admission, at 2 h, 24 h, 7–10 days, and 3 months poststroke. Here, we examined symptom progression in 11
neurologic domains as assessed by 15 individual item
subscores on the NIHSS. A description of the items/
variables is given in Table 1. We excluded a total of 135
cases who had imputed data at any time point (134)
and/or had died (118). We excluded these cases because
the imputation approach that had been used could distort patterns of change in scores for individual patients
(i.e., missing values were imputed as the worst score
for each NIHSS item). After exclusions, there were 489
remaining cases for analysis. Further, we treated time as
a series of discrete observations, 0–4, starting with the
patients’ assessment at admission. We have to treat time
discretely rather than continuously because of how the
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Table 1 NINDS tPA trial data, variable names and symptom
descriptions
Variable name

Symptom description

ATAXIA

Coordination

CONSCIO (LOC)

Level of consciousness

DYSAR (dysarthria)

Speech (slurring)

EXTIN (extinction)

Spatial perception

GAZE

Eye movements

LANG (language)

Language

LOCCOM (LOC communication)

Command following

LOCQU (LOC questionnaire)

Question answering

MOTORLA (left arm)

Left arm strength

MOTORLL (left leg)

Left leg strength

MOTORRA (right arm)

Right arm strength

MOTORRL (right leg)

Right leg strength

PALSY

Facial weakness

SENSORY

Skin sensation (pain/pinprick)

VISUAL

Visual fields

data are coded in the NINDS tPA trial database. Ideally,
we could measure time continuously in days or years,
preserving the variability in assessment times [17–19],
but that information was not available to us. Instead, in
both the mixed-effect and TPC models, we fit trajectories based on discrete time. Although this transformation of the time variable means that absolute changes in
time are arbitrary (i.e., 0–2 is 24 h, but 2–4 is potentially
3 months), relative changes in time are still meaningful
(i.e., negative slopes mean that neurological deficits were
improving over time, at the choosen timepoints) (Fig. 1).
2.1 Mixed‑effects regression model

To obtain individual trajectories for each person on the
different domains of the NIHSS, we fit a series of ordinal (cumulative link [21]) and Poisson (generalized linear [22]) mixed-models with random-intercepts and
slopes for each subject. We focus on the ordinal models
in the text because cumulative link models are designed
to handle ordered, but non-continuous, response data.
We present the Poisson models in the Additional file 1:
Appendix S1. Although these models provide a reasonable fit to the data, it is less clear that the NIHSS items
meet the assumption of treating the responses as counts
(i.e., the language item is scored as 0 = normal, 1 = mild
aphasia, 2 = severe aphasia, 3 = total/global aphasia,
but severe aphasia is not necessarily twice mild aphasia). However, the Poisson model might be more familiar
to many readers than the ordinal model, and the models
do largely agree in correlations between trajectories over
time as shown in the Additional file 1: Appendix S1. The
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Fig. 1 Data from the NINDS tPA trial shown as a function of time and the 15 NIHSS assessment items. Note that some items (e.g., ataxia) range from
0 to 2, others from 0 to 3 (e.g., language), and others from 0 to 4 (e.g., arm and leg measures). The proportion of participant obtaining that score at
each timepoint is shown via a color-coded stacked histogram (total N = 489)

models do not completely agree, however, so we defer to
the ordinal model as more appropriate given the scoring
of the NIHSS.
The NINDS dataset contains repeated measures at 5
time points across 11 different neurological domains
(as measured by 15 different NIHSS assessment items),
resulting in 75 observations per patient. To understand
how changes in different symptoms relate to each other
over time, we extracted the random-effects from each
model to get a unique trajectory for each individual in
each domain. Ideally, this estimation could be done in
a single multilevel model that nests time within each
domain within each participant. However, because the
NIHSS domains all have numerically different maxima, they cannot all be estimated in the same ordinal
model. As such, we chose to fit a unique model for each
domain, extract the slopes for each person, and then
compare those slopes across domains. Thus, it is important to remember that absolute differences in the outcome are difficult (if not impossible) to interpret (i.e., is
total sensory loss, a 2 on the sensory domain, equivalent

in severity to total gaze palsy, a 2 on the gaze domain?).
However, relative changes across domains are still meaningful (i.e., negative slopes mean improvement over time
for all domains and if the slopes are positively correlated,
that means the symptoms tend to improve together).
Models also included fixed-effects of Time, Group (tPA
versus placebo), and the Group × Time interaction. Estimates, standard errors, and p-values for all models are
presented in the Additional file 1: Appendix S1. Statistical significance was defined as (α = 0.05) for all tests.
Although the fixed-effects are presented in the results
below, we want to emphasize that demonstrating the
efficacy of tPA is not the goal of our analysis. Our goal
is to describe how individuals change over time across
domains and see which domains tend to be correlated
with each other (doing this first with mixed-effect models and then with TPC). We present the effects of Group
and the Group × Time interactions as an internal validity
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check so that these analysis can be compared to past
work showing the efficacy of tPA [33].
2.2 Trajectory profile clustering

The Trajectory Profile Clustering algorithm [27] is
designed to group together patients based on the similarities of their disease trajectories. In essence, it uses
graphical tools to generate trajectory profiles for each
individual that track their evolution of symptoms across
time, then clusters them into communities of similarly
behaving individuals that define a recovery subtype. The
algorithm proceeds as follows:
1. Model using bipartite networks At time point t we
construct a bipartite graph modeling connections
between N individuals and V disease variables/
symptoms. The connections between the individuals and symptoms are encoded through an adjacency
matrix At of size N × V . For M time points, we
can represent the set of these bipartite graphs as an
N × V × M by stacking the At across time points to
generate a tensor X where Xivt gives the value of individual i’s disease symptom v at time t.
2. Threshold and binarize to obtain trajectory profile
We threshold each symptom to set values less than a
fixed fraction κ of the maximum score for the symptom to zero. For example, if symptom ν takes score
values in (0, 1, 2, 3, 4, 5), if κ = 0.5, we binarize scores
such that scores below 5 × 0.5 = 2.5 are set to 0, and
above are set to 1. We call this thresholded matrix
the trajectory profile matrix, T i for patient i, that contains a representation of how the set of symptoms
that a patient is severely affected by varies with time.
The matrix entries of T i are calculated as follows:
i
Tνt
= 0 if Xiνt ≤ max(ν) · κ,

(1)

= 1 if Xiνt > max(ν) · κ.

(2)

Since the range of values for each symptom represents the entire scale of severity, this thresholding
ensures that patients are only considered ’connected’
to symptoms that they severely express.
3. Create a patient–patient network based on trajectory similarity We create a patient–patient network
P of all patients. The nodes of this network denote
patients, and the strength of a link between patient i
and patient j captures the similarity of their trajectory
profiles. P has an adjacency matrix given by:

j
Pij =
(Tvti ≡ Tvt ).
(3)
v,t

In other words, Pij gives the number of matrix
entries for which trajectory profile T i has the same
value as T j . This formulation implies that symptoms
are equally weighted. While the approach is amenable to non-uniform weighting, there is little clinical
consensus on the relative importance of different
symptoms. Hence, in the interest of not introducing
external bias, we choose uniform weighting, adopting an agnostic approach that assumes all symptoms/
indicators are equally important. Other applications may require unequal weighting for symptoms
and different time points, in which case one may
calculate
matrix as follows:
 the patient–patient
j
Pij = v,t wvt (Tvti ≡ Tvt ) where wvt is the weight of
symptom v at time t.
4. Cluster the network to identify subtypes We then perform Louvain community detection [37] to maximize the Newman–Girvan modularity function [38]
on the network defined by the adjacency matrix
P. Such community detection allows us to identify
’communities’ of patients, where individuals within
a community have a relatively more similar stroke
recovery profiles than patients between communities. As is common in network community detection
approaches, the number of communities is not set
a priori, but rather chosen so that the modularity is
maximized. This process allows us to cluster trajectory profiles, and hence patients, into subtypes which
have high intra-subtype similarity. The subtypes are
denoted by C 1 , C 2 , . . . C L, where each C l is a collection of trajectory profiles of the patients in that subtype, and L is the total number of subtypes.
5. Construct aggregate profiles to characterize each subtype: We average the trajectory profiles of all patients
in each community C l to obtain the ‘community/subtype profile’ S l . The subtype profile is indicative of the
symptom features that describe the subtype. More
specifically, it is the normalized average of the trajectory profiles of all the patients in that subtype, i.e., S l
is a V × M matrix with elements defined by

i
l T
l
Svt
= i∈C vt ,
(4)
Nl
where Nl is the total number of individuals in subtype C l.
2.3 Graph neural network

Graph neural networks (GNNs) [30] are a machine learning approach that captures the relationships represented
in graphs through message passing between the nodes of
those graphs. GNNs take a graph as input and pass them
several layers of nodes, artificial ‘neurons’. Here we use
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graph neural networks to identify the timepoints that are
most relevant in determining stroke recovery subtypes.
Specifically, we train a graph neural network on symptom–symptom graphs generated at each timepoint, and
test the accuracy of a GNN in its ability to classify an
individual into the correct recovery subtype using data
from a single timepoint. A higher accuracy at a given
timepoint implies that the recovery subtypes attributed
to the patients are strongly correlated with the symptom
profiles at that timepoint.
We generate a symptom–symptom interaction graph
Gt at each timepoint t where the nodes represent the
disease symptoms. This graph is undirected (i.e., if node
x is connected to node y, vice-versa is also true, i.e., the
adjacency matrix of this graph is symmetric). The graph
is generated as follows. First we generate a symptom–
patient binary interaction network for a given timepoint
as in step (3) of the previous section. We then project
it to symptom space to obtain the symptom interaction
profile of each patient at a timepoint. The corresponding
adjacency matrix (of size V × V ) for the graph for patient
i is given by
T
Git = Tivt
× Tivt .

(5)

Lastly, We repeat this for each individual such that there
exist N symptom–symptom interaction graphs at each
timepoint.
We then separate the individual cases into a training
data set (70% of total individuals) and a test data set (30%
of total individuals) used to validate our approach. A convolutional graph neural network is trained on a graph
classifying task for each time point, with labels provided
by the subtypes/communities of that individual. The
stratification of individuals into their recovery subtypes
at each timepoint is then measured by testing the accuracy of the GNN on the test data for each timepoint.
The graph neural network takes as input symptom–
symptom networks where we consider the 15 NIHSS
assessment items as the nodes. The network consists of
an input layer, a single hidden layer, and an output layer.
The hidden layer comprises 64 artificial neurons. The
input is processed through two graph convolutional layers with ReLU nonlinearities. We then calculate the
graph representation by averaging all the neuron representations in the output layer, which contains an equal
number of neurons to the number of subtypes. The output is passed through a softmax classifier that yields the
probability of the graph belonging to a particular category/subtype. We use cross-entropy loss and the adaptive
moment estimation (ADAM) optimizer.

3 Results
3.1 Key patterns in slopes from the ordinal mixed‑effect
models

Full details of the models are presented in the Additional file 1: Appendix S1. In brief, however, there were
statistically significant negative effects of Time for several different domains of the NIHSS: LOC (b = − 0.43),
dysarthria (b = − 0.76), visual extinction (b = − 0.38),
gaze (b = − 0.68), language (− 0.39), the left arm (b=−
0.99), the right arm (b = − 0.65), the left leg (b = −
0.66), the right leg (b = − 0.55), palsy (b = − 0.67),
and sensation (b = − 0.39), showing that neurological
deficits generally improved over time. Consistent with
prior analyses of these data [11], there were also statistically significant effects of Group for extinction (b =
+ 0.51), the left leg (b = + 0.49), the right leg (b = +
0.74), and sensation (b = + 0.38), and Group × Time
interactions for dysarthria (b = + 0.13), the left arm (b
= + 0.36), and palsy (b = + 0.15), which showed that
the placebo group fared worse overall or improved
more slowly over time in several domains compared to
the tPA group.
Inspection of the person-level coefficients of this
model also provides some insights relevant to the current goal of creating behavioral phenotypes. As shown
in Fig. 2, and as would be expected given the common
occurrence of post-stroke hemiplegia (weakening on
one side of the body), some of the strongest correlations
were for the ipsilateral arm and leg. The right arm and
leg showed a similar timecourse of change in impairment
(r = 0.80), as did the left arm and leg (r = 0.81). Second,
there are also patterns in the correlation matrix consistent with lateralization of function as affected by unilateral stroke. For instance, the NIHSS item for extinction
was positively associated with left arm/leg deficits (both
from right hemisphere damage; r = 0.36 − 0.40), and
much less associated with right arm/leg deficits (from
left hemisphere damage; r = 0.08 − 0.14 ). Gaze was also
positively associated with extinction r = 0.53, possibly
reflecting the fact that gaze deviation is typically more
pronounced in patients with hemineglect [39]. Lastly,
language was positively associated with the right arm/
leg (all left hemisphere effected; r = 0.56 − 0.57) and
trivially associated with the left arm/leg (which are right
hemisphere effected, r = − 0.07 − 0.04).
In sum, ordinal mixed-effect regression provides us
with analytical replication of past work (i.e., the superiority of tPA to placebo as shown in several different
domains of the NIHSS) and new insights into how sets
of symptoms co-evolve over time. However, these correlations between individual trajectories do not tell us
which individuals cluster together nor do they provide
us clear guidance on where cut-offs between different
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Fig. 2 Correlogram showing the association between slopes in the different domains of the NIHSS. Correlations are shown as Spearman rank-order
correlations. Red boxes indicate positive correlations and blue colors indicate negative correlations

groups of individuals should be drawn, or when clusters
begin to show reliable separation. There multiple analytical approaches that one could take to achieve these aims
(e.g., cluster analysis of the random-slopes at successive
timepoints could theoretically achieve this goal following the mixed-effect models). Acknowledging the diversity of possible methods, we present TPC as a pragmatic
method that can both establish the common multidimensional trajectories that individuals tend to show and classify those individuals based on their trajectories.
3.2 Stroke recovery subtypes identified by TPC

Maximizing modularity on the patient–patient trajectory-similarity network gives us three distinct recovery
subtypes. It is worth mentioning that the number of subtypes are not predetermined, but are optimally chosen
such that the modularity is maximized, i.e., the subtypes
are optimally separated.
Figure 3 shows the clinical profiles of each subtype. The
darkness of the shade of grey for each symptom over time
denotes the fraction of patients who had a value above
threshold for that symptom. To reiterate, the thresholding ensures that patients are only considered affected
with symptoms for which they display relatively high

severity, defined to be above the population median. Our
analysis identifies 3 distinct stroke trajectory profiles that
align with clinically relevant stroke syndromes, characterized both by distinct clusters of symptoms, as well as
differing degrees of symptom severity over time. Several
key features of the identified subtypes warrant comment.
First, our TPC approach identifies a ‘mildly affected’
group that was the least symptomatic of the three subtypes both in terms of baseline severity and 3-month
residual symptoms. As a group, this subtype showed a
mixture of features that are not clearly lateralizing. In
addition, two severely affected subtypes are readily identified that correspond to left and right hemisphere syndromes: We find a ‘left motor’ subtype, showing severely
impaired left arm and leg strength together with hemineglect, but with essentially no right-sided motor symptoms
(red boxes, Fig. 3), and a ‘right motor’ subtype, showing severely impaired right arm and right leg strength
together with aphasia (blue boxes, Fig. 3). Additionally,
spatial perception scale items are most affected in the
‘left motor’ group (corresponding clinically to a right
hemisphere syndrome with hemispatial neglect). Conversely, the language and question-answering items are
most affected in the ‘right motor’ group (corresponding
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for hemineglect symptoms in both left- and right-hemisphere stroke, since persistent milder symptoms that
could be amenable to treatment might otherwise be overlooked. Visual deficits are also present in both left- and
right-hemisphere strokes as would be expected, but contrary to conventional understanding that visual deficits
resolve less well than hemineglect, the overall prevalence
of persistent visual symptoms at 3 months is lower than
for hemineglect.
3.2.1 Effects of tPA treatment and time

Fig. 3 Corresponding profiles of the 3 stroke recovery subtypes.
Subtypes identified by the algorithm containing fewer than 10
patients are not shown (1 outlier patient falls under this category).
The shade of grey indicates the affected fraction, i.e., fraction of
patients in the recovery subtype that are severely affected by that
symptom at that time. The number of patients in the subtype, and
fraction of patients receiving treatment is listed above each panel.
The symptom names are listed to the left. The red boxes highlight
the unique combination of dominant symptoms of the ‘left motor’
subtype. The blue boxes highlight the unique combination of
dominant symptoms of the middle ‘right motor’ subtype. The
rightmost ‘mildly affected’ subtype has the mildest symptom profile.
The symptoms names on the left are preceded by the letter ‘S’
(indicating ‘Stroke’) to be consistent with the naming convention in
the dataset

to a left hemisphere syndrome with primarily expressive
aphasia). These findings are in alignment with prior factor analysis on the clinimetric properties of the NIHSS
[40] and principal component analysis (PCA) to define
common behavioral clusters [41], as well as results from
our mixed-effects model in Sect. 3.1. The fact that our
results capture clinically relevant subtypes and corroborate these prior findings supports the content validity
of this analytic approach. Additionally, our clustering
approaches reveal subtype structure at a finer scale (both
in terms of symptoms as well as longitudinal symptom
evolution) than can be achieved with PCA, and results
that are clinically consistent.
It is notable that all three identified trajectory subtypes
included both tPA- and placebo-treated patients, suggesting that treatment effects were less defining characteristics of patient recovery profiles than were initial severity
and stroke laterality. TPC also provides interesting
insights into patterns of symptom prevalence over time
across subtypes. Spatial perception deficits (hemineglect)
are present in both the left-motor and right-motor subtypes, but tend to be milder and have better resolution in
left hemisphere strokes. This observation reinforces the
importance of targeted screening during rehabilitation

A natural extension of our TPC subtyping is to study
the timecourse of stratification into these subtypes. One
might wonder whether subtype (and consequently the
expected recovery profile of a patient) is largely driven
by baseline symptom severity or by early stroke treatments. Machine learning is particularly well-posed to
answer such questions. Since we operate in the graph
domain, we use graph neural networks. We first extract
trajectory profiles independently on patients who had
received tPA within 3 h of stroke onset compared to
patients who had received a placebo. In Fig. 4, we see
that the identified subtypes retain the same symptom
clusters identified in Fig. 3, but that overall symptom
severity is lower in the tPA-treated population (Fig. 4A),
particularly in symptoms that are dominant identifiers of
the group. For instance, in the left-motor group, assessment items for gaze, left arm and leg strength, and pain/
pinprick sensation showed higher recovery in the tPAtreated group (Fig. 4A) versus placebo group (Fig. 4B).
Similarly, in the right-motor group, assessment items
for right arm and leg strength, and command-following
(SLOCCOM) showed higher recovery in the tPA-treated
group (Fig. 4A) compared to the placebo group (Fig. 4B).
As expected, the effect of tPA is less obvious in the minimally impaired group. We explore in Fig. 5 the accuracy
of a neural network in predicting the subtype of an individual given data at a discrete timepoint. We generated
a symptom-interaction network for each individual at
each timepoint, and trained a convolutional-GNN to
learn properties of interaction with neighbors. The convolutions are used for averaging over the neighborhood.
If the learned properties for that timepoint are separated
according to subtypes, then data at that timepoint is considered a good predictor of the subtype. In the training
stage, we assume that the subtype is known to the neural
network, which attempts to learn correlations between
symptom-interaction patterns and the subtype. We then
test to identify if the features learned by the neural network are consistent with the actual subtypes of the test
patients.
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Fig. 4 Trajectory profiles (same as in the above figure) were applied independently on patients that A received tissue plasminogen activator (tPA)
treatment within 3 h of stroke onset compared to B patients who received placebo. Subtypes identified by the algorithm containing fewer than 10
patients are not shown (1 outlier patient falls under this category). The shade of grey indicates the affected fraction

Fig. 5 Test accuracy denoting predictive power of a graph neural
network as a function of timepoint. Accuracy plotted separately
for patients that received tPA treatment, placebo patients and all
patients (tPA treated+placebo). 70% data used for training the neural
network, 30% for testing. Number of training epochs = 100. We use a
2 layer graph convolutional neural network with 16 hidden units and
relu nonlinearity at both layers

Figure 5 shows that there is a difference in predictive
accuracy at baseline for the tPA vs. Placebo groups. The
baseline timepoint is a more accurate predictor of subtype for patients who received tPA. This finding may
seem unexpected if one posits that tPA ‘rescues’ an otherwise poor prognosis with severe baseline symptoms
predicting poor outcomes. However, the predictive accuracy for the tPA group rapidly increases during the first

2 h, and given the expected timecourse for therapeutic
effects of tPA, this finding provides additional validation
of our approach. For the Placebo group, predictive accuracy grows at comparable rates (comparable slopes) up to
the 24-h mark, showing peak predictive accuracy at the
7–10 day mark, with standard error on the order 10−2.
The tPA group showed a further uptick in predictive
accuracy by the 3-month mark, suggesting that treatment
continues to exert an effect on recovery subtype stratification even in the later stages of post-stroke. One might
speculate that this is the result of tPA treatment salvaging
a greater ‘reserve’ of neural tissue for later rehabilitation
therapies to act upon. Our report on the rapid increase in
predictive accuracy from 2 to 24 h post-stroke furthermore aligns with recent work by Heitsch et al. [42] who
reported on the early change in NIHSS scores between 6
and 24 h as a dynamic phenotype associated with longterm outcomes.

4 Conclusion and future work
In this work we introduce a network-based, data-driven
method for stroke recovery analysis. First, we analyze
the NINDS tPA stroke dataset using conventional quantitative medicine methods including a ordinal mixedeffects regression model, examining the effects of time,
group (tPA vs. Placebo), and their interactions across
neurological domains. Further, to identify stroke recovery subtypes and examine their characteristics at a finer
resolution, we use the Trajectory Profile Clustering
method which accounts not only for symptom severity
at different timepoints, but also symptom interactions
and their temporal evolution. Of note, although the
analytical approach is clinically agnostic, we identify
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subtypes that are clinically relevant. In particular, we
identify a mildly affected recovery subtype comprising a larger proportion of patients who received tPA.
Additionally, we observed that the two other recovery
subtypes stratify as left- versus right-sided hemiplegia.
Additionally, we identified that left motor deficits are
strongly correlated with deficits in gaze and extinction,
whereas right motor deficits correlated with deficits in
language. These results again are biologically relevant,
and are further validated by convergent findings in the
mixed-effects regression models. Lastly, we use graph
neural networks to study how much of the stratification into subtypes is identifiable at different time
points, and found that stroke recovery trajectories were
largely defined within the first 24 h, consistent with the
expected pharmacodynamics of tPA treatment delivered in the first 3 h after stroke.
This paper is the first work introducing network trajectory approaches for stroke recovery phenotyping,
and is aimed at enhancing the translation of such novel
computational approaches for practical clinical application. This work presents a data-driven method that
is widely applicable to heterogenous neurological disorders such as stroke, and bridges the fields of predictive medicine and network informatics. Because our
approach is uniquely adapted to accommodate input
variables on multiple scales, future applications could
include the integration of other types of data that may
contribute to the heterogeneity of recovery, such as
data on patient genotypes.
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